Role of Luteolin-Induced Apoptosis and Autophagy in Human Glioblastoma Cell Lines

Hye-Sung Lee1, Bong-Soo Park2,3, Hae-Mi Kang2

  • 1Department of Oral and Maxillofacial Surgery, School of Dentistry, Pusan National University, Yangsan-si 50612, Korea.

Medicina (Kaunas, Lithuania)
|September 28, 2021
PubMed

Insights

Luteolin, a natural flavonoid, induces apoptosis and autophagy in glioblastoma cells. Combining luteolin with an autophagy inhibitor may improve glioblastoma treatment outcomes.

Area of Science:

  • Molecular Biology
  • Cancer Research
  • Pharmacology

Background:

  • Malignant glioblastoma (GBM) exhibits poor therapeutic outcomes with conventional treatments.
  • Luteolin, a natural flavonoid, possesses known anti-inflammatory and anti-cancer properties.
  • The interplay between luteolin-induced apoptosis and autophagy in GBM remains unexplored.

Purpose of the Study:

  • To investigate the induction of apoptosis and autophagy by luteolin in glioblastoma cells.
  • To elucidate the relationship between luteolin-induced apoptosis and autophagy in GBM.

Main Methods:

  • Utilized A172 and U-373MG glioblastoma cell lines.
  • Assessed luteolin's effects using MTT assays, immunofluorescence, flow cytometry (FACS), Western blot, and qPCR.
  • Investigated autophagy's role using 3-methyladenine (3MA) as an inhibitor.

Main Results:

  • Luteolin decreased glioblastoma cell viability in a dose- and time-dependent manner.
  • Observed characteristic apoptosis markers (nuclear fragmentation, caspase-3, PARP cleavage) at higher luteolin concentrations (>100 μM).
  • Luteolin induced autophagy at lower concentrations (≥50 μM), and autophagy inhibition enhanced luteolin-induced apoptosis.

Conclusions:

  • Luteolin effectively induces both apoptosis and autophagy in glioblastoma cells.
  • Luteolin-induced autophagy appears to promote glioblastoma cell survival.
  • Combination therapy with luteolin and autophagy inhibitors shows potential for improving GBM treatment prognosis.